Entering text into the input field will update the search result below

Revance sees cash burn as high as $137M this year, U.S. marketing application for TR002 expected in 2019

Jan. 04, 2018 12:36 PM ETRevance Therapeutics, Inc. (RVNC) StockBy: Douglas W. House, SA News Editor4 Comments
  • Revance Therapeutics (NASDAQ:RVNC -0.6%) expects operations to consume $117M - 137M in cash this year as it winds up clinical development of DaxibotulinumtoxinA for Injection (RT002) for the treatment of glabellar lines (frown lines). Assuming positive results from a long-term safety study, expected to be completed in H2, a U.S. marketing application should be filed in H1 2019.
  • The company plans to launch a Phase 3 trial assessing RT002 in cervical dystonia, an Orphan Drug indication, in Q2.
  • Preliminary results from a Phase 2a proof-of-concept study of RT002 in plantar fasciitis should be released within the next several weeks.
  • Related ticker: AGN

Recommended For You

About RVNC Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RVNC--
Revance Therapeutics, Inc.